In addition to its traditional and highly cross-functional role to support the introduction and application of our medicines, the scope of regional medical affairs is rapidly evolving into an essential function to inform Pfizer's research strategy via formalized input into asset strategic plans and to contribute to our medicine's life-cycles, e.g. via scientific discussion of IIR-Proposals.
Recently, regional medical affairs assumed additional responsibility on opportunities to enhance the drug label according to regional needs through planning and execution of Clinical Research Collaborations (CRCs). In the future, the evaluation and collection of real-world evidence - in collaboration with other internal and external stakeholders - will be another essential task for our group. Ultimately, a key role of medical is to analyze and translate the needs of healthcare providers/systems and to communicate the value of our medicines through clinical concepts and evidence.
To succeed in today's oncology research, it is essential to have a clear evidence strategy in a highly dynamic, increasingly complex, and competitive environment.
Your tasks and responsibilities:
- Provide biostatistical input to medical affairs teams for design, planning and conduct of analyses of clinical trials and observational studies as well as post-hoc analyses of existing databases and meta-analyses
- Provide expertise on statistical planning with focus on patient-relevant endpoints, such as patient-reported outcomes.
- Build up knowledge in scientific methods for real life evidence projects for example, observational studies, epidemiology, "low intervention" trials
- Liaise with country access / health & value functions to support local reimbursement efforts and to inform global evidence strategy
- Review of research proposals (IIRs) and validation / quality control of statistic reports, e.g. by investigators
- Train medical affairs staff in general and indication-specific statistical concepts
- Be ambassador for Pfizer's methodological approaches and participate in scientific debate, e.g. about endpoints in oncology